# Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

> **NCT03261791** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT03261791
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07-20
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-04-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261791, "Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03261791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*